Form 4: Akero Therapeutics COO Jonathan Young Reports Stock Sale

Jonathan Young, COO of Akero Therapeutics, reports the sale of 10,000 shares of common stock on October 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 1, 2024, Jonathan Young, the Chief Operating Officer of Akero Therapeutics, sold 10,000 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan established on June 25, 2024.
• The shares were sold at a weighted-average price of $28.177, with individual transactions ranging from $27.72 to $28.67.
• Following the transaction, Young directly owns 226,286 shares of Akero Therapeutics.
• Young also reports indirect ownership of 20,000 shares each through three irrevocable trusts for the benefit of his children, with his spouse as trustee.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting an insider stock sale. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

This filing is a routine disclosure of insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale by a key executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates